Walgreens Shareholders Approve $10 Billion Private Equity Buyout

Walgreens Boots Alliance shareholders have overwhelmingly approved Sycamore Partners' $10 billion buyout offer, with 96% voting in favor. The deal values WBA at $11.45 per share, a 29% premium over its December price, and includes a potential additional $3 per share from the future monetization of its VillageMD primary care assets. This approval follows WBA's significant financial struggles, including an over $8 billion net loss in FY2024 largely due to the costly VillageMD investment, and is intended to accelerate the company's turnaround under private ownership, with closing expected in Q3/Q4 subject to regulatory approvals.

Analysis

Walgreens Boots Alliance shareholders have decisively approved the $10 billion buyout by Sycamore Partners, with a 96% vote in favor, signaling a clear mandate for a strategic overhaul under private ownership. The transaction values WBA at $11.45 per share—a 29% premium to its December stock price—sweetened by a contingent value right (CVR) of up to $3 per share tied to the future monetization of its VillageMD assets. This buyout is a direct consequence of the company's severe financial underperformance, highlighted by a fiscal 2024 net loss exceeding $8 billion, which was primarily attributed to the failed expansion of its VillageMD primary care clinics. The previous strategy, which involved a more than $6 billion investment to gain a controlling stake in VillageMD, was aggressively scaled back by CEO Tim Wentworth after clinics failed to attract sufficient patient volumes. The move to go private is presented by management as a necessary step to accelerate a turnaround away from public market pressures, effectively ending a disastrous chapter of capital misallocation that eroded a market value that stood at over $100 billion a decade ago. The negative per-ticker sentiment for WBA (-0.2) accurately reflects these deep-seated fundamental issues, even as the deal itself provides a floor for the stock price and a path forward, subject to regulatory approval expected in the second half of the year.

Key Decisions for Investors

• With shareholder approval secured, investors should anticipate WBA's stock to trade closely to the $11.45 offer price, with any discount reflecting the time value of money and the residual risk of regulatory hurdles prior to the expected Q3/Q4 close.
• The key variable for total shareholder return is now the contingent value right, as the potential $3 per share from the VillageMD monetization is highly uncertain and dependent on Sycamore's ability to salvage value from assets that previously generated an $8 billion loss for WBA.
• This transaction underscores the significant execution risk in vertically integrated healthcare models, prompting investors in the retail pharmacy sector to scrutinize competitors' similar strategies for signs of unsustainable capital expenditure or operational friction.